KG207 / KalGene Pharma - LARVOL DELTA

Pharmacokinetics and Pharmacodynamic Effect of a Blood-Brain Barrier-Crossing Fusion Protein Therapeutic for Alzheimer's Disease in Rat and Dog. (PubMed, Pharm Res) - "This study demonstrates translational attributes of BBB-crossing Aβ-targeting biotherapeutic KG207-H in eliciting a pharmacodynamic response, from rodents to larger animal species."

Journal • PK/PD data • Preclinical • Alzheimer's Disease • CNS Disorders

KalGene Pharmaceuticals, Inc. announces a new peer-review publication demonstrating the efficacy of KG207 in clearing toxic oligomer species of amyloid beta in translational imaging studies (PRNewswire) - "KalGene Pharmaceuticals, Inc. announces a new peer-review publication demonstrating the efficacy of KG207 in clearing toxic oligomer species of amyloid beta in translational imaging studies....The study highlights the importance of designing pre-clinical studies using translational outcomes and assessment modalities that are typically used in clinical trials for AD. The evidence presented in this article shows a great potential of KG207 as a disease-modifying therapy for Alzheimer's disease."

Preclinical • Alzheimer's Disease • CNS Disorders